NCT02517021 · OUTCOME

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase

A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting · Source last updated 2018-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 0-120 hours

Groups in this outcome

Pro-netupitant/Palonosetron Plus Dexamethasone

Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Pro-netupitant/Palonosetron Dexamethasone

Netupitant/Palonosetron Plus Dexamethasone

Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Netupitant/Palonosetron Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Pro-netupitant/Palonosetron Plus Dexamethasone	203
Netupitant/Palonosetron Plus Dexamethasone	201

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Pro-netupitant/Palonosetron Plus Dexamethasone	156	Not reported	Not reported	Not reported	Not reported
Netupitant/Palonosetron Plus Dexamethasone	169	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
156
group Id
OG001
value
169

denoms

counts
group Id
OG000
value
203
group Id
OG001
value
201
units
Participants

groups

description
Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Pro-netupitant/Palonosetron Dexamethasone
id
OG000
title
Pro-netupitant/Palonosetron Plus Dexamethasone
description
Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle Netupitant/Palonosetron Dexamethasone
id
OG001
title
Netupitant/Palonosetron Plus Dexamethasone

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

0-120 hours

title

Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice